SAM
IONS icon

Silvercrest Asset Management’s Ionis Pharmaceuticals IONS Stock Holding History

Silvercrest Asset Management’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$559K Buy
7,055
+2
+0% +$151 ﹤0.01% 687
2026
Q1 		$530K Sell
7,053
-189
-3% -$14.9K ﹤0.01% 681
2025
Q4 		$573K Buy
7,242
+124
+2% +$9.34K ﹤0.01% 700
2025
Q3 		$466K Buy
7,118
+50
+0.7% +$2.44K ﹤0.01% 704
2025
Q2 		$279K Buy
7,068
+166
+2% +$5.43K ﹤0.01% 775
2025
Q1 		$208K Buy
6,902
+285
+4% +$9.33K ﹤0.01% 814
2024
Q4 		$231K Buy
+6,617
New +$247K ﹤0.01% 791

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Silvercrest Asset Management's IONS Position: Q2 2026 in Review

Silvercrest Asset Management increased its Ionis Pharmaceuticals (IONS) stake by 0.03% in Q2 2026, buying an estimated $151 and bringing the position to 7,055 shares worth $559K. The position accounts for ﹤0.01% of the portfolio, ranked #687.

Silvercrest Asset Management first reported a position in IONS in Q4 2024 and has held it in 7 quarters since. The position peaked at $573K in Q4 2025. 514 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

  • Silvercrest Asset Management held 7,055 shares of Ionis Pharmaceuticals worth $559K as of Q2 2026.
  • Silvercrest Asset Management bought 2 Ionis Pharmaceuticals shares in Q2 2026, an estimated $151.
  • Ionis Pharmaceuticals made up ﹤0.01% of Silvercrest Asset Management's portfolio in Q2 2026, its #687 holding.
  • Silvercrest Asset Management first reported a position in Ionis Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • Silvercrest Asset Management's Ionis Pharmaceuticals position peaked at $573K in Q4 2025.
  • 514 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on Silvercrest Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.